Literature DB >> 30826126

Young-age onset colorectal cancer in Brazil: Analysis of incidence, clinical features, and outcomes in a tertiary cancer center.

Andrea C B Silva1, Maria Fernanda B Vicentini2, Elizabeth Z Mendoza2, Fernanda K Fujiki2, Leonardo G da Fonseca2, Maria Ignez F M Braghiroli2, Paulo M Hoff2.   

Abstract

BACKGROUND: Recent studies report increasing incidence of colorectal cancer (CRC) in the young-age population, but data concerning clinical behavior, pathologic findings, and prognosis are controversial for this group. Early recognition of CRC in young patients is a challenge and diagnosis at advanced stage is clearly associated with worse outcomes.
MATERIALS AND METHODS: We retrospectively reviewed medical records of 5806 patients diagnosed with CRC between January/2011 and November/2016 and identified 781 patients aged less than 50-years-old.
RESULTS: We found an absolute increasing in the incidence of CRC in patients <50 years old of 1.88%-2.23% annually, with a relative increasing of 35.3% between 2011 and 2016. Median age was 42 years, 57.4% were female and 20.9% reported family history of CRC. Left-sided tumors were more frequent and the majority of patients were symptomatic. The most common stages at diagnosis were III (34.1%) and IV (37.3%). The median overall survival (OS) for stage IV was 25 months (95% CI 20.7-29.3) and was not reached for Stages I-III (P < 0.001). Family history of CRC was independently associated with better OS in stage IV(P = 0.02). For stages I-III, wild-type KRAS, family history of CRC, and absence of angiolymphatic invasion were associated with better OS (P = 0.02, P = 0.01 and P < 0.001, respectively).
CONCLUSIONS: In our cohort, the incidence of early-onset CRC is increasing over the past years. Young patients were more likely to be diagnosed with metastatic disease, left-sided and/or rectum site and symptoms at presentation. These findings highlight the emerging importance of young-age onset CRC and the need to discuss strategies to early diagnosis.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Early-onset; Epidemiology; Screening; Survival

Year:  2019        PMID: 30826126     DOI: 10.1016/j.currproblcancer.2019.01.009

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN: 0147-0272            Impact factor:   3.187


  5 in total

1.  Young patients with benign anal diseases and rectal bleeding: should a colonoscopy be performed?

Authors:  Belisa G Muller; Paulo C Contu; Cláudio Tarta; Anderson R Lazzaron; Tiago L Ghezzi; Daniel C Damin
Journal:  Int J Colorectal Dis       Date:  2019-11-09       Impact factor: 2.571

2.  The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil.

Authors:  Wânia Cristina da Silva; Brian Godman; Francisco de Assis Acúrcio; Mariângela Leal Cherchiglia; Antony Martin; Konrad Maruszczyk; Jans Bastos Izidoro; Marcos André Portella; Agner Pereira Lana; Orozimbo Henriques Campos Neto; Eli Iola Gurgel Andrade
Journal:  Appl Health Econ Health Policy       Date:  2021-01-28       Impact factor: 2.561

Review 3.  An Update on the Epidemiology, Molecular Characterization, Diagnosis, and Screening Strategies for Early-Onset Colorectal Cancer.

Authors:  Andrea N Burnett-Hartman; Jeffrey K Lee; Joshua Demb; Samir Gupta
Journal:  Gastroenterology       Date:  2021-01-05       Impact factor: 22.682

4.  Clinical, Pathological and Molecular Characteristics of Chilean Patients with Early-, Intermediate- and Late-Onset Colorectal Cancer.

Authors:  Karin Alvarez; Alessandra Cassana; Marjorie De La Fuente; Tamara Canales; Mario Abedrapo; Francisco López-Köstner
Journal:  Cells       Date:  2021-03-12       Impact factor: 6.600

5.  Age-Related and Gender-Related Increases in Colorectal Cancer Mortality Rates in Brazil Between 1979 and 2015: Projections for Continuing Rises in Disease.

Authors:  Francis L Martin; Camilo L M Morais; Juliana Yumi Sakita; Sergio Akira Uyemura; Vinicius Kannen
Journal:  J Gastrointest Cancer       Date:  2021-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.